exenatide glp 1 agonist Further support for GLP-1R agonists – The Science of Parkinson's GLP1 receptor agonist @nejm revisión

This builds on his work to understand 'how circulating GLP-1 can produce multiple actions, both directly and indirectly, on multiple organs' which he has pursued for many years with colleagues (McLean, Wong, Campbell)

But we know that when you take them for years, if you have heart disease, that youre more likely to be alive than if you get a placebo instead

[DOI] [PubMed] [Google Scholar] 27.Irace C., De Luca S., Shehaj E., Carallo C., Loprete A., Scavelli F., Gnasso A

Furthermore, the STEP-TEENS trial demonstrated semaglutides effectiveness in reducing BMI and cardiometabolic risks in obese adolescents, suggesting its potential for use in younger populations (40)

International Journal of Molecular Sciences 24